Day One Biopharmaceuticals (DAWN)
(Delayed Data from NSDQ)
$6.88 USD
+0.15 (2.15%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $6.15 -0.73 (-10.61%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
DAWN 6.88 +0.15(2.15%)
Will DAWN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DAWN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DAWN
Wall Street Analysts Believe Day One Biopharmaceuticals (DAWN) Could Rally 303.46%: Here's is How to Trade
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q1 Loss, Tops Revenue Estimates
DAWN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Jazz Stock Gains as Q4 Earnings & Sales Surpass Expectations
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Tops Revenue Estimates
Perrigo Gears Up to Report Q4 Earnings: Here's What to Expect
Other News for DAWN
Day One Biopharmaceuticals, Inc. 2025 Q2 - Results - Earnings Call Presentation
Day One Biopharmaceuticals outlines $140M–$150M 2025 OJEMDA revenue target as new patient scripts accelerate
Day One Biopharmaceuticals, Inc. (DAWN) Q2 2025 Earnings Call Transcript
Day One Biopharmaceuticals Non-GAAP EPS of -$0.29 beats by $0.05, revenue of $33.91M misses by $0.99M
Day One Biopharmaceuticals GAAP EPS of -$0.29, revenue of $33.9M